Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 91-100 , April 2010

Management of prostate cancer recurrence after definitive radiation therapy

  • Christian Boukaram

      Affiliations

    • Department of Radiation Therapy, Maisonneuve-Rosemont Hospital, 5415 Bd de l’Assomption, Montreal, Quebec, Canada H1T 2M4
    • Department of Radiation Therapy, Antoine Lacassagne Cancer Center, 33, Avenue de Valombrose, 06189 Nice Cedex, France
    • ,
  • Jean-Michel Hannoun-Levi

      Affiliations

    • Department of Radiation Therapy, Antoine Lacassagne Cancer Center, 33, Avenue de Valombrose, 06189 Nice Cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 492 031 271; fax: +33 492 031 570.

Received 3 April 2009 ,Revised 8 June 2009 ,Accepted 21 June 2009.

References 

  1. Allen GW, Howard AR, Jarrard DF, et al. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer. 2007;110:1405–1416
  2. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.
  3. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. New Engl J Med. 2008;358:1250–1261
  4. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–1129
  5. Ogawa K, Nakamura K, Sasaki T, et al. Radical external beam radiotherapy for prostate cancer in Japan: differences in the patterns of care among Japan, Germany, and the United States. Japanese Patterns of Care Study Working Subgroup of Prostate Cancer. Radiat Med. 2008;26:57–62
  6. Wilson L, Tesoro R, Elkin R, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007;109:518–527
  7. Khuntia D, Reddy CA, Mahadevan A, et al. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?. Cancer. 2004;100:1283–1292
  8. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915–928
  9. Nguyen P, D’amico AV, Lee AK, et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure. Cancer. 2007;110:1417–1428
  10. Abramowitz MC, Li T, Buyyounouski MK, Ross E, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008;112:55–60
  11. Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol. 1982;6:541–551
  12. Stephenson AJ, Scardino PT, Bianco FJ, et al. Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy. Curr Treat Options Oncol. 2004;5:357–365
  13. Chalasani V, Martinez CH, Lim D, et al. Salvage HIFU for recurrent prostate cancer after radiotherapy. Prostate Cancer Prostatic Dis 2008 October 14 [Epub].
  14. Novo JF, Lopez SP, Aguilo FL, et al. Diagnostic methodology for the biochemical recurrence of prostate cancer after radiotherapy. Arch Esp Urol. 2006;59:1053–1062
  15. Gleave ME, Coupland D, Drachenberg D, et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology. 1996;47:708–712
  16. Greco C, Cascini GL, Tamburrini O. Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse?. Prostate Cancer Prostatic Dis. 2008;11:121–128
  17. Pucar D, Sella T, Schoder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol. 2008;18:87–97
  18. Rinnab L, Simon J, Hautmann RE, et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009 February 21 [Epub].
  19. Cirillo S, Petracchini M, D’Urso L, et al. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound. BJU Int. 2008;102:452–458
  20. Pucar D, Shukla-Dave A, Hricak H, et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology. 2005;236:545–553
  21. Lemaitre L, Rouviere O, Penna-Renard R, et al. MRI and prostate cancer: a paradigm shift. J Radiol. 2008;89:1053–1063
  22. Ben Cheikh A, Girouin N, Ryon-Taponnier P, et al. MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results. J Radiol. 2008;89:571–577
  23. Kim CK, Park BK, Lee HM, et al. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol. 2008;190:1180–1186
  24. Chan K, Byung K, Hyun L, et al. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging. 2009;29:391–397
  25. Kwee T, Takahara T, Ochiai R, et al. Diffusion-weighted whole body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008;18:1937–1952
  26. Luboldt W, Küfer R, Blumstein N, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology. 2008;249:1017–1025
  27. Crook J, Malone S, Perry G, et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48:355–367
  28. Molinié V, Mahjoub WK, Balaton A. Histological modifications observed in prostate after preserving treatments for prostate cancer and their impact on Gleason score interpretation. Ann Pathol. 2008;28:363–373
  29. Leventis AK, Shariat SF, Kattan MW, et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001;19:1030–1039
  30. Heidenreich A, Semrau R, Thuer D, et al. Radical salvage prostatectomy: treatment of local recurrence of prostate cancer after radiotherapy. Urologe A. 2008;47:1441–1446
  31. Hautmann RE. Salvage radical prostatectomy. Urologe A. 2006;45:1260–1265
  32. Leibovici D, Spiess PE, Heller L, et al. Salvage surgery for locally recurrent prostate cancer after radiation therapy: tricks of the trade. Urol Oncol. 2008;26:9–16
  33. Ward JF, Sebo TJ, Blute ML, et al. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005;173:1156–1160
  34. Boris RS, Bhandari A, Krane LS, et al. Salvage robotic-assisted radical prostatectomy: initial results and early report of outcomes. BJU Int 2008 December 2 [Epub].
  35. Paparel P, Cronin AM, Savage C, et al. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. Eur Urol 2008 July 14 [Epub].
  36. Bianco FJ, Scardino PT, Stephenson AJ, et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:448–453
  37. Sanderson KM, Penson DF, Cai J, et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol. 2006;176:2025–2031
  38. Gheiler EL, Tefilli MV, Tiguert R, et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 1998;51:789–795
  39. Ahlering TE, Lieskovsky G, Skinner DG. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol. 1992;147:900–902
  40. Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year follow-up. J Urol. 1998;159:950–954
  41. Van der Poel HG, Beetsma DB, van Boven H, et al. Perineal salvage prostatectomy for radiation resistant prostate cancer. Eur Urol. 2007;51:1565–1571
  42. Pisters LL, English SF, Scott SM, et al. Salvage prostatectomy with continent catheterizable urinary reconstruction: a novel approach to recurrent prostate cancer after radiation therapy. J Urol. 2000;63:1771–1774
  43. Onik G, Cohen JK, Reyes GD, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72:1291–1299
  44. Chin JL, Pautler SE, Mouraviev V, et al. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol. 2001;165:1937–1941
  45. Chin JL, Touma N, et al. Current status of salvage cryoablation for prostate cancer following radiation failure. Technol Cancer Res Treat. 2005;4:211–216
  46. Eisenberg ML, Shinohara K. Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology. 2008;72:1315–1318
  47. Chin JL, Lim D, Abdelhady M, et al. Review of primary and salvage cryoablation for prostate cancer. Cancer Contr. 2007;14:231–237
  48. Pisters LL, von Eschenbach AC, Scott SM, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997;157:921–925
  49. Blana A, Murat FJ, Walter B, et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol. 2008;53:1194–1201
  50. Izawa JI, Madsen LT, Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol. 2002;20:2664–2671
  51. Benoit RM, Cohen JK, Miller RJ. Cryosurgery for prostate cancer: new technology and indications. Curr Urol Rep. 2000;1:41–47
  52. Bahn DK, Lee F, Silverman P, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer. 2003;2:111–114
  53. Donnelly BJ, Saliken JC, Ernst DS, et al. Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. Prostate Cancer Prostatic Dis. 2005;8:235–242
  54. Ghafar MA, Johnson CW, De La Taille A, et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol. 2001;166:1333–1337
  55. Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology. 1999;53:2–10
  56. Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67:1106–1112
  57. Nguyen P, Chen MH, D’Amico AV, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer. A prospective phase 2 study. Cancer. 2007;110:1485–1492
  58. Tharp M, Hardacre M, Bennett R, et al. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy. 2008;7:231–236
  59. Lee HK, Adams MT, Motta J. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Brachytherapy. 2008;7:17–21
  60. Aaronson D, Yamasaki I, Gottschalk A. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009 February 23 [Epub].
  61. Koutrouvelis P, Hendricks F, Lailas N, et al. Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat. 2003;2:339–344
  62. Loening SA, Turner JW. Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. Prostate. 1993;23:283–290
  63. Lo K, Stock RG, Stone NN. Salvage prostate brachytherapy following radiotherapy failure. Int J Radiat Oncol Biol Phys. 2005;63:290–291
  64. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology. 1999;54:880–883
  65. Wong WW, Buskirk SJ, Schild SE, et al. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol. 2006;176:2020–2024
  66. Dattoli M, Cash J, Ross R, et al. Neoadjuvant hormone therapy and palladium-103 brachytherapy as salvage for locally recurrent prostate cancer. Proc Am Soc Clin Oncol. 1997;16:1118
  67. Hannoun-Levi JM, Benezery K, Bondiau PY, et al. Radiothérapie robotisée des cancers de prostate par CyberKnife™. Cancer/Radiothérapie. 2007;11:476–482
  68. Olsen C. SBRT vs HDR as hypofractionnated radiation therapy for prostate cancer: a comparison of achievable Tumor and Normal tissue doses. In: Proceedings of the 48th annual ASTRO meeting, vol. 2310; 2008. p. S383.
  69. King C, Brooks JD, Gill H. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043–1048
  70. Pasticier G, Chapet O, Badet L, et al. Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Urology. 2008;72:1305–1309
  71. Poissonnier L, Murat FJ, Belot A, et al. Adénocarcinome prostatique en récidive locale après radiothérapie exclusive: résultats du traitement par ultrasons focalisés. Prog Urol. 2008;18:223–229
  72. Gelet A, Chapelon JY, Poisonnier L, et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology. 2004;63:625–629
  73. Zacharakis E, Ahmed HU, Ishaq A, et al. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int. 2008;102:786–792
  74. Murat FJ, Poissonnier L, Rabilloud M, et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 2008 May 9 [Epub].
  75. Ahmed HU, Ishaq A, Zacharakis E, et al. Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. BJU Int. 2009;103:321–323
  76. Trachtenberg J, Bogaards A, Weersink RA, et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol. 2007;178:1974–1979
  77. Boustead G, Edwards SJ. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials. BJU Int. 2007;99:1383–1389
  78. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009 February 21 [Epub].
  79. Prapotnich D, Cathelineau X, Rozet F, et al. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results. World J Urol 2009 February 27 [Epub].
  80. Dale W, Hemmerich J, Bylow K, et al. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J Clin Oncol 2009 March 2 [Epub].
  81. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009;115(27):2388–99.
  82. Loprinzi CL, Dueck AC, Khoyratty BS, et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol. 2009;20:542–549
  83. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–3983
  84. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27:92–99
  85. Tsai HK, D’Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–1524
  86. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl. 2008;29:534–539
  87. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. New Engl J Med. 2005;352:154–164
  88. Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;26:5465–5476
  89. Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008;26:4426–4434
  90. Nelson CJ, Lee JS, Gamboa MC, et al. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113:1097–1106
  91. Lee R, Hanks G, Hanlon A, et al. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol. 1997;15:230–238
  92. Cheng L, Sebo T, Slezak J, et al. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer. 2009;83:2164–2171
  93. Ng CK, Moussa M, Downey DB, et al. Salvage cryoablation of the prostate: follow-up and analysis of predictive factors for outcome. J Urol. 2007;178:1253–1257
  94. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439
  95. Buyyounouski MK, Hanlon AL, Horwitz EM. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:59–66
  96. Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25:1765–1771
  97. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997;44:213–221
  98. D’Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New Engl J Med. 2004;351:125–135
  99. Lee AK, D’Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol. 2005;23:8192–8197
  100. RTOG Prostate Cancer Protocols. RTOG 0526. A prospective phase II trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate adenocarcinoma following external beam radiotherapy. <http://www.rtog.org/members/protocols/0526/0526.pdf> [accessed 04.02.09].
  101. FSI-003 Trial. A multicenter clinical study of the Sonoblate 500 (SB 500) for the treatment of locally recurrent prostate cancer with HIFU. <http://www.clinicaltrials.gov/archive/NCT00772317/2008_10_14> [accessed 04.02.09].

PII: S0305-7372(09)00092-9

doi: 10.1016/j.ctrv.2009.06.006

Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 91-100 , April 2010

Article Tools

* Image Usage & Resolution